Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
BrightGene Bio-Medical Technology Co., Ltd. clinical trials
The registry lists 18 studies whose lead sponsor is BrightGene Bio-Medical Technology Co., Ltd. or one of 1 company grouped under it. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the BrightGene Bio-Medical Technology Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to BrightGene Bio-Medical Technology Co., Ltd..
- BrightGene Bio-Medical Technology Co., Ltd.17 studiesSame company
Something wrong?
- BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.1 study →Subsidiary
Something wrong?
Focus areas
Conditions BrightGene Bio-Medical Technology Co., Ltd. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 18 of 18.
- A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without DiabetesRecruitingNCT07658560Phase 2
- A Study of BGM0504 in Early T2DM With ObesityRecruitingNCT07743983Phase 3
- Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult SubjectsCompletedNCT07166081Phase 1
- Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and WomenActive, not recruitingNCT07224399Phase 1
- Bioequivalence Study of BGM0504 InjectionCompletedNCT07382908Phase 1
- A Study of BGM0504 Injection in Participants With Obesity or OverweightCompletedNCT06704581Phase 3
Sponsor listed in the registry: BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.
- A Study of BGM0504 in Participants With Type 2 DiabetesActive, not recruitingNCT06716216Phase 3
- A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExerciseActive, not recruitingNCT06716203Phase 3
- A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese ParticipantsCompletedNCT07294235Phase 1
- A Study of BGM0504 in Participants With ObesityCompletedNCT06911203Phase 2
- A Study of BGM0504 in Overweight or Obese ParticipantsCompletedNCT06920056Phase 1
- A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal FunctionCompletedNCT06929156Phase 1
- A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese SubjectsCompletedNCT06973681Phase 2
- A Study of BGM0504 in Participants With Type 2 Diabetes in IndonesiaActive, not recruitingNCT07064486Phase 3
- A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese SubjectsCompletedNCT07239973Phase 1
- A Study of BGM0504 Tablets in Healthy Chinese SubjectsCompletedNCT07566572Phase 1
- Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult SubjectsCompletedNCT06714955Phase 1
- A Study of BGM0504 in Chinese Patients With Type 2 DiabetesCompletedNCT06974825Phase 2